# Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

> **NCT04901741** · PHASE2 · NOT_YET_RECRUITING · sponsor: **TME Pharma AG** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Olaptesed pegol
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04901741
- **Lead sponsor:** TME Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2028-03
- **Final completion:** 2029-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901741, "Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04901741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*